Switching between GLP-1 medications: what changes, what doesn't, what to ask

TLDR. People switch GLP-1s for cost, side effects, a stalled scale, or a supply or coverage change. Some switches are easy. Going from Ozempic to Wegovy keeps the same molecule (semaglutide), so the dose carries over. Some switches restart the clock. There is no validated milligram-for-milligram swap between semaglutide and tirzepatide, so that move usually means starting the new drug at its lowest dose and titrating up again. None of this is a decision you make alone. Your prescriber sets the dose and the timing. This page explains the moving parts so you walk into that conversation knowing what to ask.

Why people switch

Most switches trace back to one of five reasons. Sometimes two at once.

Cost. This is the big one, and it is our beat. A program that fit your budget last quarter can change its price, drop a discount, or move you off an introductory rate. Compounded semaglutide can run several times cheaper than brand Wegovy, which pulls people one direction. A new insurance approval can make brand cheaper than cash compounded, which pulls them back. Run your real monthly number on the GLP-1 cost guide before you move.

Side effects. Nausea, constipation, and other gut symptoms are the most common reason people want off a given drug. The two molecules have overlapping side effect profiles, so switching molecules is not a guaranteed fix. Often the better first move is a slower titration or a dose hold, not a new drug. See the side effects guide for what is normal and what is not.

A stall. The scale stops moving six to nine months in. Sometimes the answer is more dose on the same drug. Sometimes it is a different molecule. We wrote a full decision piece on that exact fork: titrate or switch when you plateau. Read it before you assume the drug quit working.

Supply or availability. Shortages and compounding-pharmacy shutdowns push people onto whatever they can actually get. When a 503A or 503B source goes dark, the practical switch is to brand or to another supplier.

Coverage or program change. Your insurer changes its formulary, your employer drops weight-loss coverage, or your telehealth program changes what it dispenses. Any of these can force a move you did not plan. If your coverage just changed, start with what to do when your insurance changes.

The easy switch: same molecule, different label

Two pairs of products are the same active ingredient under two brand names. These switches are the simplest because the drug in the syringe does not change.

Ozempic and Wegovy are both semaglutide. Ozempic is approved for type 2 diabetes. Wegovy is approved for chronic weight management and for cutting cardiovascular risk in certain patients. The dose ladders differ slightly. Ozempic tops out at a 2.0 mg weekly maintenance dose. Wegovy's standard maintenance dose is 2.4 mg weekly, and a higher 7.2 mg dose now exists for patients who tolerate 2.4 mg and need more. Because the molecule is identical, a prescriber can usually map your current dose across rather than start you at zero. The brand and the indication change. The active drug does not. See Ozempic and Wegovy for the full profiles.

Mounjaro and Zepbound are both tirzepatide. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Both run the same dose ladder from 2.5 mg up to 15 mg weekly. We covered the quirks of this pair in Mounjaro vs Zepbound, same drug different rules. See Mounjaro and Zepbound for details.

The reason these matter for switching: a same-molecule move is mostly a paperwork and pricing change. The hard switches are the ones where the molecule itself changes.

The hard switch: changing molecules

Going from semaglutide to tirzepatide, or the reverse, is a different drug with a different mechanism. Semaglutide acts on one incretin receptor. Tirzepatide acts on two. That difference is why their doses do not line up.

There is no 1:1 milligram conversion. This is the single most important thing to understand. Neither drug's label contains a conversion table, because no validated equivalence exists. Charts that claim "2.4 mg semaglutide equals X mg tirzepatide" are not official and should not be trusted. A 1.0 mg dose of one drug is not a 1.0 mg dose of the other in any meaningful sense.

So a molecule switch usually restarts titration. Because there is no safe way to dose-match, the standard approach is to start the new drug at its lowest dose and step up again. Zepbound and Mounjaro begin at 2.5 mg weekly. Wegovy and Ozempic begin at 0.25 mg weekly. Each step is held about four weeks to let the gut adjust. That means a few months at sub-maintenance dosing while you climb back up. Plan for it. People often see weight hold steady or tick up slightly during the rebuild, then resume falling once the higher dose lands.

For the data on which molecule does more, and where the side-effect and coverage differences sit, read tirzepatide vs semaglutide head to head. The short version: in a direct trial in type 2 diabetes (SURPASS-2, NEJM 2021), tirzepatide beat semaglutide on weight and blood sugar, though the comparison used semaglutide's 1 mg dose. In obesity trials, semaglutide 2.4 mg averaged about 14.9 percent weight loss (STEP-1, NEJM 2021) and tirzepatide 15 mg averaged about 21 percent (SURMOUNT-1, NEJM 2022). The molecules are not interchangeable, and the right one depends on your health profile, not on which trial number is bigger.

Brand to compounded, and back

A compounded version uses the same active ingredient as the brand, made by a compounding pharmacy. The most common switch here is cash compounded semaglutide standing in for brand Wegovy on price. Because the molecule is the same, the dose usually carries over and the transition is smooth.

Going the other way, from compounded back to brand, happens for specific reasons: a new insurance approval, a supply scare, a plateau at the compounded dose ceiling, or pregnancy and surgery plans. We laid out that whole decision in compounded to brand, when to make the move. One caution worth repeating: the active drug is the same, so most people transition cleanly, but brand and compounded formulations can use different inactive ingredients, so a little breakthrough nausea on the first brand dose is not unusual.

Oral and injectable are not the same dose

Rybelsus is oral semaglutide, a tablet taken once daily at 3 mg, 7 mg, or 14 mg. It is approved for type 2 diabetes, not for weight loss. Here is the trap: oral and injectable semaglutide are not milligram-equivalent. Oral absorption is very low, on the order of 1 percent, so a 14 mg daily tablet is not the same exposure as a 1.0 mg weekly injection. You cannot convert one to the other yourself. A prescriber maps the change.

Note one more wrinkle. An oral semaglutide tablet for weight management now exists, dosed separately from Rybelsus and at a higher strength. It is a different product from the diabetes tablet. If a switch involves any oral form, confirm exactly which product and which indication you are talking about, because the names are easy to mix up.

Washout and overlap: don't double up

When you switch between two once-weekly GLP-1s, the labels do not require a fixed washout period. The practical concern is the opposite of a gap. You do not want to stack two long-acting drugs on top of each other.

Semaglutide has a half-life of about one week, which is why it is dosed weekly. Tirzepatide's half-life is about five days. Because both linger, the common clinical approach is to give your last dose of the old drug, then start the new drug at the time your next dose would have been due, roughly a week later. No overlap, no doubling. This is standard practice rather than a hard rule printed in the label, so your prescriber may adjust the timing to your situation. Confirm the exact day before you switch.

What to ask your prescriber

Switching is a clinical decision. Walk in with these questions and you will get a better answer.

• Is this a same-molecule switch or a new molecule? If new, what dose do I start at, and how long until I am back to a full dose?
• What dose do I take on which day during the transition? When is my last old dose and my first new dose?
• Should I expect the scale to stall while I re-titrate? For how long?
• What side effects are normal in the first few weeks on the new drug, and what is a reason to call you?
• Does my insurance cover the new drug, and do we need a fresh prior authorization?
• If the reason is cost, is there a cheaper version of the same molecule that would solve this without changing drugs?
• If the reason is a stall, is more dose on my current drug an option before we switch molecules?

The cost angle

Cost is the most common reason to switch, and it is the easiest one to get wrong. The instinct is to chase the lowest headline price. The better move is to price the full monthly cost of each real option, then switch once into the cheapest one that fits, rather than bouncing between programs every billing cycle.

Three tools do most of the work. The main chart compares programs side by side on ongoing monthly price. The drug pages break down each medication and its cheaper same-molecule versions. The price index tracks where prices sit right now. If your only goal is to pay less for the same molecule, you may not need to switch drugs at all. You may just need a different program dispensing the one you are already on.

Some visit links earn us a commission.

Frequently asked questions

Can I switch from Ozempic to Wegovy at the same dose?

Often yes, because they are the same molecule, semaglutide. The dose ladders differ slightly at the top, so your prescriber confirms the mapping, but a same-molecule switch usually does not mean starting over at the lowest dose. The brand and the approved use change. The active drug does not.

Do I have to restart at the lowest dose when I switch from semaglutide to tirzepatide?

Usually yes. There is no validated milligram-for-milligram conversion between the two molecules, so the standard approach is to start the new drug at its lowest dose and titrate up again. For tirzepatide that means 2.5 mg weekly to start. Expect a few months back at sub-maintenance dosing while you climb.

Is there a washout period between two GLP-1 medications?

The labels do not require a fixed washout when switching between two once-weekly GLP-1s. The common practice is to take your last dose of the old drug, then start the new drug when your next dose would have been due, about a week later, without overlapping. Your prescriber sets the exact timing.

Will switching molecules stop my nausea?

Not reliably. Semaglutide and tirzepatide have overlapping gut side effects, so a switch is not a guaranteed fix for nausea or constipation. A slower titration or a temporary dose hold on your current drug often helps more. Talk to your prescriber before assuming a new molecule will solve it.

Can I switch from Rybelsus to an injectable to lose weight?

Rybelsus is oral semaglutide approved for type 2 diabetes, not weight loss, and oral and injectable doses are not equivalent because oral absorption is very low. Any move from an oral tablet to an injection is a prescriber decision, not a dose you convert yourself.

Does switching drugs reset my weight loss progress?

A same-molecule switch generally does not. A molecule switch can pause it, because you spend a few months re-titrating at lower doses before reaching a full dose again. Weight often holds or rises slightly during the rebuild, then resumes falling. The net effect over the following months is usually further weight loss, not lost ground.

Is it cheaper to switch drugs or switch programs?

Frequently it is cheaper to switch programs, not drugs. If your goal is a lower price for the medication you already take, a different program dispensing the same molecule can solve it without restarting titration. Compare ongoing monthly prices on the chart first.

Before you switch

This page is education, not medical advice, and glpchart does not prescribe. Switching a GLP-1 changes your dose, your timing, and sometimes your whole drug, and the safe version of that decision runs through a licensed prescriber who knows your history. Use this to ask sharper questions. Let the clinician make the call.